We evaluated the ability of the CDK inhibitor SNS-032 to impair TNBC cell survival and growth, and we demonstrated the elevation of PD-L1 expression by surviving cancer cells after treatment with suboptimal doses of SNS-032 in vitro and in a human xenograft model of triple-negative breast cancer. Here, CD274 is linked to triple-negative breast carcinoma.